NCT05432804 2026-03-18
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
National Cancer Institute (NCI)
Phase 1/2 Suspended
National Cancer Institute (NCI)
Mayo Clinic
AHS Cancer Control Alberta
Weill Medical College of Cornell University
Petrov, Andrey
Emory University
Northwell Health
Northwell Health
Precision Life Sciences Group
Universitätsmedizin Mannheim
Cortice Biosciences, Inc.
InSightec